University of Groningen
Oncogenic variants guiding treatment in thoracic malignancies Meng, Pei
DOI:
10.33612/diss.160074057
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2021
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Meng, P. (2021). Oncogenic variants guiding treatment in thoracic malignancies. University of Groningen. https://doi.org/10.33612/diss.160074057
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Oncogenic variants guiding treatment in
thoracic malignancies
Meng, P
Oncogenic variants guiding treatment in thoracic malignancies
Thesis, University of Groningen, Groningen, The Netherlands
Printing of this thesis was financially supported by the university of Groningen, the Graduate School of Medical Sciences, University of Groningen.
Cover: Pei Meng
Layout: Pei Meng
Printed by: Gildeprint | www.gildeprint.nl
Copyright © 2021, P. Meng, The Netherlands
All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, mechanically, by photocopying, recording, or otherwise without prior written permission of the author.
Oncogenic variants guiding
treatment in thoracic malignancies
PhD thesis
to obtain the degree of PhD at the University of Groningen
on the authority of the
Rector Magnificus Prof. C. Wijmenga and in accordance with
the decision by the College of Deans. This thesis will be defended in public on
Monday 15 March 2021 at 11.00 hours
by
Pei Meng
born on 5 September 1990 in Hunan, China
Supervisors
Prof. J.H.M. van den Berg Prof. H.J.M. Groen
Co-supervisors
Dr. K. Kok
Dr. A.J. van der Wekken
Assessment Committee
Prof. H.A.M. Kerstjens Prof. M.R. Groves Prof. B. Sorensen
Paranymphs
Yichen Liu Weiting Li
Contents
Chapter 1 Introduction and scope of this thesis 9
Chapter 2 An all-in-one transcriptome-based assay to identify therapy-guiding genomic aberrations in non-small cell lung cancer patients
(Cancers. 2020 Oct; 12(10): 2843)
29
Chapter 3 Detecting therapy-guiding RNA aberrations in platelets of non-small cell lung cancer patients
(medRxiv. 2021 Jan 26)
61
Chapter 4 Concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated
NSCLC treated with dabrafenib and trametinib 81
Chapter 5 Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small cell lung cancer patients with an osimertinib-induced BRAF V600E mutation
(Lung Cancer. 2020 Aug; 146: 358-361)
97
Chapter 6 Clinical value of EGFR copy number gain determined by amplicon-based targeted next generation sequencing in EGFR mutated NSCLC patients
(In revision)
105
Chapter 7 Targeted sequencing of circulating cell-free DNA in stage II-III resectable esophageal squamous cell carcinoma patients (BMC Cancer.2019 Aug 20; 19(1): 818)
125
Chapter 8 Summary, discussion and future perspectives 155
Appendices Dutch summary (Nederlandse samenvatting) 169
